Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.58 |
| ▸ | YARS1 | P54577 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 2/20 | 0.49 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | CPA1 | P15085 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29697108 | 0.97 | SLC7A5 (0.55) | SLC7A5YARS1MEN1KMT2AMME | |
| SCHEMBL30712170 | 0.94 | ENPEP (0.54) | SLC7A5YARS1MEN1KMT2AMME | |
| SCHEMBL31121651 | 0.94 | ENPEP (0.54) | SLC7A5YARS1MEN1KMT2AMME | |
| SCHEMBL30123118 | 0.93 | OPRD1 (0.56) | MMEOPRD1OPRM1OPRK1 | |
| SCHEMBL29730651 | 0.93 | MME (0.52) | SLC7A5YARS1MMEENPEP | |
| SCHEMBL29839256 | 0.93 | OPRD1 (0.56) | MMEOPRD1OPRM1OPRK1 | |
| SCHEMBL29630566 | 0.92 | OPRD1 (0.55) | MMEOPRD1OPRM1OPRK1 | |
| SCHEMBL30494285 | 0.91 | SLC7A5 (0.51) | SLC7A5YARS1ENPEPOPRD1 | |
| SCHEMBL30149609 | 0.91 | ENPEP (0.53) | SLC7A5YARS1MEN1KMT2AMME | |
| SCHEMBL29697056 | 0.91 | ENPEP (0.53) | SLC7A5YARS1MEN1KMT2AMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12377110-B2 | Fospropofol methods and compositions | EPALEX CORPORATION (US) | 2025-08-05 | — | — | US | claimed |
| CN-115836732-A | High-altitude functional adhesive with functions of hypoxia resistance and immunity enhancement and preparation method thereof | 中国人民解放军陆军勤务学院 | 2023-03-24 | — | — | CN | claimed |
| US-20230084521-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2023-03-16 | — | — | US | claimed |
| US-20220105050-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2022-04-07 | — | — | US | claimed |
| US-20250312361-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | EPALEX CORP (US) | 2025-10-09 | — | — | US | disclosed |
| US-12377110-B2 | Fospropofol methods and compositions | EPALEX CORPORATION (US) | 2025-08-05 | — | — | US | disclosed |
| CN-115873803-B | Method for improving NK cell survival and anti-tumor activity and application thereof | 上海恩凯细胞技术有限公司 | 2025-06-17 | — | — | CN | disclosed |
| WO-2025109003-A1 | P-CADHERIN LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-05-30 | — | — | WO | disclosed |
| CN-120005928-A | Dynamic regulation and control system, strain, construction method of strain and application of strain in microbial fuel cell | 天津科技大学 | 2025-05-16 | — | — | CN | disclosed |
| CN-117264928-B | Acetylcholinesterase crystal from aspergillus niger GZUF and preparation method and application thereof | 贵州大学 | 2025-04-18 | — | — | CN | disclosed |
| CN-118909996-A | Galactosyltransferase mutant and application thereof in preparation of flavonoid compounds | 浙江大学 | 2024-11-08 | — | — | CN | disclosed |
| CN-118813570-A | Flavone glycosyltransferase, mutant and application thereof | 井冈山大学 | 2024-10-22 | — | — | CN | disclosed |
| US-20230084521-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2023-03-16 | — | — | US | disclosed |
| WO-2023285489-A1 | OVERCOMING ANTIBODY-INTERFERENCE IN AVIANS | INTERVET INTERNATIONAL B.V. (NL) | 2023-01-19 | — | — | WO | disclosed |
| CN-115044652-A | Nucleic acid detection kit based on CRISPR/Cas12a system and up-conversion luminescent particle immunochromatography and application | 中国人民解放军军事科学院军事医学研究院 | 2022-09-13 | — | — | CN | disclosed |
| CN-113388620-B | FcCGA 1 gene related to citrus disease resistance, primer pair, silencing vector and application | 赣南师范大学 | 2022-08-26 | — | — | CN | disclosed |
| US-20220265686-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2022-08-25 | — | — | US | disclosed |
| CN-114807105-A | Lyase with strong temperature tolerance, preparation method and application | 吉林大学 | 2022-07-29 | — | — | CN | disclosed |
| WO-2022136555-A1 | IMPROVED CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2022-06-30 | — | — | WO | disclosed |
| US-20220105050-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2022-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312361-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | FOS, FOSB, PFAS | SLC7A5 2919/4885YARS1 4808/4885MEN1 797/4885 |
| US-12377110-B2 | Fospropofol methods and compositions | FOS, FOSB, PFAS | SLC7A5 2919/4885YARS1 4808/4885MEN1 797/4885 |
| US-20220265686-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | FOS, FOSB, PFAS | SLC7A5 2919/4885YARS1 4808/4885MEN1 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.